Piper Jaffray analyst William Quirk raised his price target for Illumina to $329 and keeps an Overweight rating on the shares ahead of the company's Q2 results. Channel checks found 43 NovaSeqs in Q2, which suggests Illumina likely placed 86 in the quarter, in line to slightly higher than the consensus estimate of 84 systems, Quirk tells investors in a research note. The analyst believes the company is "rapidly evolving from a stock dominated by the latest instrument release to a multi-faceted growth story." Illumina is "driving market changing approaches, particularly in the clinical space," the analyst writes. Olson sees upside and near and longer term estimates.